重新评估CD30检测在淋巴瘤诊断与治疗中的价值
该综述结合WHO-HAEM5、ICC 2022、关键临床试验及国际共识,系统总结CD30在不同淋巴瘤中的表达特点、免疫组化判读原则与病理报告规范。重点阐述IHC仍是首选检测方法,维布妥昔单抗疗效与CD30表达水平并非简单线性相关,部分低表达甚至常规IHC未检出者仍可获益。
要点
- IHC仍是CD30检测的首选方法,报告应描述定位、强度、比例及分布模式。
- 维布妥昔单抗疗效与CD30表达水平并非简单线性相关。
- 低表达或常规IHC未检出CD30的患者仍可能从CD30靶向治疗中获益。
核心结论
- CD30检测的临床价值已由辅助病理分型扩展至治疗决策支持和实验室规范化管理。
- 维布妥昔单抗疗效与CD30表达水平并非简单线性相关,部分低表达甚至常规IHC目测未检出表达的患者仍可能从CD30靶向治疗中获益。
研究设计与样本
- 综述结合WHO第5版造血与淋巴组织肿瘤分类(WHO-HAEM5)、2022国际共识分类(ICC)、重要临床试验及国内外专家共识进行系统总结。
主要发现
- 综述总结了CD30在不同淋巴瘤中的表达特点、IHC判读原则、病理报告规范、CD30靶向治疗相关证据及实验室质量控制要求。
- IHC仍是CD30检测的首选方法。
- 病理报告宜采用描述性方式,完整记录肿瘤细胞CD30表达的定位、强度、比例及分布模式。
关键数值与推荐
- 维布妥昔单抗及其联合方案在经典霍奇金淋巴瘤、外周T细胞淋巴瘤、皮肤CD30阳性T细胞淋巴增殖性疾病及复发/难治性弥漫大B细胞淋巴瘤等疾病中的关键临床研究不断更新。
- 病理实验室应将前处理、质量控制、判读标准、复核机制及异质性识别纳入规范化检测流程。
临床怎么用
- 病理报告宜采用描述性方式完整记录CD30表达的定位、强度、比例及分布模式。
- 病理实验室应将前处理、质量控制、判读标准、复核机制及异质性识别纳入规范化检测流程。
- 本文提出的CD30检测流程、质量控制要点、常见问题及病理报告建议可为病理诊断、实验室质量管理及临床多学科诊疗提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD30 is a pivotal immunohistochemical marker for the diagnosis of selected lymphoid neoplasms and an important biomarker that informs clinical consideration of CD30-targeted therapy. With the expanding clinical application of brentuximab vedotin (BV) and BV-based regimens in classical Hodgkin lymphoma, peripheral T-cell lymphoma, primary cutaneous CD30-positive T-cell lymphoproliferative disorders, and relapsed/refractory diffuse large B-cell lymphoma, the clinical role of CD30 testing has evolved beyond conventional diagnostic classification to encompass therapeutic decision-making and laboratory quality management. This review integrates the 5th edition of the WHO classification of haematolymphoid tumours (WHO-HAEM5), the International Consensus Classification (ICC, 2022), pivotal clinical trials, and recent international consensus recommendations to summarize the expression patterns of CD30 across different lymphoma subtypes, principles for immunohistochemical interpretation, standardized pathology reporting, evidence supporting CD30-targeted therapy, and key quality assurance requirements for laboratory practice. Particular emphasis is placed on the following concepts: immunohistochemistry remains the preferred method for CD30 assessment; pathology reports should adopt a descriptive approach that documents the localization, staining intensity, proportion, and distribution pattern of CD30-positive tumor cells; the clinical benefit of brentuximab vedotin is not simply correlated with the level of CD30 expression, as some patients with low-level expression or even no detectable CD30 expression by visual assessment of conventional immunohistochemistry may still derive therapeutic benefit; and standardized pre-analytical handling, quality control, interpretation criteria, review procedures, and recognition of intratumoral heterogeneity should be incorporated into routine laboratory practice. Practical recommendations regarding CD30 testing workflows, quality assurance, common diagnostic pitfalls, and pathology reporting are also provided to facilitate standardized pathology practice, laboratory quality management, and multidisciplinary clinical decision-making. CD30是某些淋巴瘤病理诊断及CD30靶向治疗评估的重要免疫标志物。近年来,维布妥昔单抗及其联合方案在经典霍奇金淋巴瘤、外周T细胞淋巴瘤、皮肤CD30阳性T细胞淋巴增殖性疾病及复发/难治性弥漫大B细胞淋巴瘤等疾病中的关键临床研究不断更新,CD30检测的临床价值已由辅助病理分型进一步扩展至治疗决策支持和实验室规范化管理。该文结合WHO第5版造血与淋巴组织肿瘤分类(WHO-HAEM5)、2022国际共识分类(ICC)、重要临床试验及国内外专家共识,系统总结CD30在不同淋巴瘤中的表达特点、免疫组织化学(IHC)判读原则、病理报告规范、CD30靶向治疗相关证据及实验室质量控制要求。该文重点阐述:IHC仍是CD30检测的首选方法;病理报告宜采用描述性方式,完整记录肿瘤细胞CD30表达的定位、强度、比例及分布模式;维布妥昔单抗疗效与CD30表达水平并非简单线性相关,部分低表达甚至常规IHC目测未检出表达的患者仍可能从CD30靶向治疗中获益;病理实验室应将前处理、质量控制、判读标准、复核机制及异质性识别纳入规范化检测流程。本文同时提出CD30检测流程、质量控制要点、常见问题及病理报告建议,为病理诊断、实验室质量管理及临床多学科诊疗提供参考。.
引用
- Zhao RR, Fu Y, Fan XS, et al. [Reappraisal of the value of CD30 testing in the diagnosis and treatment of lymphoma]. Zhonghua Bing Li Xue Za Zhi. 2026. PMID: 42967623. doi:10.3760/cma.j.cn112151-20260409-00259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。